CONTENT

This web page has the following on the web site, "This site is intended for US-based." Our analyzers saw that the web site also said " Is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA." The Website also said " ORENCIA may be used as monotherapy or concomitantly with disease-modifying, anti-rheumatic drugs DMARDs other than tumor necrosis factor TNF antagonists." The website's header had Rheumatoid arthritis; RA; moderate to severe RA; early as the most important optimized keyword. It is followed by rapidly progressing RA; RA first-line biologic; ORENCIA first-line biologic efficacy; ORENCIA prescribing resources; RA T cells; T cells in RA; RA biologic efficacy; ORENCIA safety which isn't as ranked as highly as Rheumatoid arthritis; RA; moderate to severe RA; early.